Dr. Martignetti on Next-Generation Sequencing in Fallopian Tube Cancer

John A. Martignetti, MD, PhD
Published: Monday, Sep 18, 2017



John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.

Next-generation sequencing technology has changed what we can see, explains Martignetti. The level of detail is greatly increased, which has benefitted the treatment landscape of fallopian tube cancer and ovarian cancer.

Circulating tumor DNA can detect cancers earlier, can provide prognostic information, and even has potential for use in screening, states Martignetti.
 


John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.

Next-generation sequencing technology has changed what we can see, explains Martignetti. The level of detail is greatly increased, which has benefitted the treatment landscape of fallopian tube cancer and ovarian cancer.

Circulating tumor DNA can detect cancers earlier, can provide prognostic information, and even has potential for use in screening, states Martignetti.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x